Galderma Group AG (XSWX:GALD) YoY EPS Growth: 126.54% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:GALD Galderma Group AG XSWX:GALD
16 GF Score
Price CHF171.55
! 3 Warning Signs
View Full Analysis

What is Galderma Group AG YoY EPS Growth?

Galderma Group AG XSWX:GALD +1.39% 16 YoY EPS Growth is 126.54% as of Jun. 2026. GuruFocus rates XSWX:GALD with a GF Score™ of 16/100. The stock has 3 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Galderma Group AG's YoY EPS Growth for the quarter that ended in Jun. 2026 was 126.54%.

Galderma Group AG's Earnings per Share (Diluted) for the six months ended in Jun. 2026 was CHF1.51.

Galderma Group AG YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG YoY EPS Growth Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
0.00 35.45 46.37 517.87 137.69

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EPS Growth Get a 7-Day Free Trial 1,093.33 409.46 272.63 104.22 126.54
XSWX:GALD
16GF Score
Galderma Group AG XSWX:GALD
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Galderma Group AG's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(2.056-0.865)/ | 0.865 |
=137.69 %

Galderma Group AG's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(1.511-0.667)/ | 0.667 |
=126.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 126.54% mean?
Galderma Group AG (XSWX:GALD) has a YoY EPS Growth of 126.54% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Galderma Group AG and its competitors.
Is Galderma Group AG's YoY EPS Growth too high?
Galderma Group AG's current YoY EPS Growth is 126.54%. Overall, Galderma Group AG has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's YoY EPS Growth compare to ZTS and UTHR?
Galderma Group AG's YoY EPS Growth of 126.54% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Drug Manufacturers company?
A good YoY EPS Growth depends on the Drug Manufacturers industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Galderma Group AG and its competitors. Galderma Group AG's current YoY EPS Growth is 126.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current YoY EPS Growth of 126.54%. The current YoY EPS Growth is 126.54%. Galderma Group AG's overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current YoY EPS Growth is 126.54% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
16GF Score

Get the complete analysis for XSWX:GALD

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF171.55
Price